Facilities

End-to-end mammalian and microbial biologics development and cGMP manufacturing, from cell line and process development to drug substance and aseptic drug product.

End-to-end mammalian and microbial biologics development and cGMP manufacturing, integrating drug substance and drug product capabilities.

End-to-end plasmid DNA and viral vector development and cGMP manufacturing, with dedicated BSL-2 viral clearance and BSL-3 laboratory capabilities.

End-to-end development and cGMP manufacturing of autologous and allogeneic cell therapies, with integrated 3D bioprinting capabilities.